[Effect of bezafibrate therapy on serum and lipoprotein lipids].
D001629:Bezafibrate / Q000494:pharmacology / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D001629:Bezafibrate
Bezafibrát kezelés hatása a szérum és lipoprotein lipidekre.